UNSPSC 51182217: Carboprost methyl ester

This classification denotes a prostaglandin analogue with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVV9BU3089, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, methyl ester, (5z,9.alpha.,11.alpha.,13e,15s)-, but more generally known as carboprost methyl ester, which bears US NIH Compound Identifier 6434195.

European Medicines Agency schedules carboprost methyl ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06615MIG. Most nations, for tariff purposes, schedule carboprost methyl ester under HS 29375000. SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC)O)O)O.

UNSPSC 51182217 Carboprost methyl ester is a Commodity code covering pharmaceutical products, specifically prostaglandin-class injectables used in obstetric and gynecological settings. State and local government procurement under this code flows through multistate cooperative purchasing vehicles that bundle generic pharmaceuticals and over-the-counter products into master agreements distributed across state health departments, local public health agencies, hospital systems, and corrections facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary buying vehicle surfacing in recent activity, with participating jurisdictions spanning Minnesota, Oregon, and other allied states. Solicitations under this code require vendors to hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with authorized wholesalers (typically AmerisourceBergen Drug Corporation/Cencara, Cardinal Health, and Morris & Dickson Co., LLC), and deliver pricing in flat-price, net-price, or WAC-minus formats. Vendors must carry $5 million commercial general liability coverage, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties ranging from $200 to $1,500 per violation for late reporting or onboarding failures.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, through June 30, 2028. Award values are not disclosed, but pricing competitiveness carries 75 percent evaluation weight, with smaller shares assigned to fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Specific award values or budget ranges are not disclosed in solicitation materials. The procurement does not identify set-aside designations or restrictions to particular business classifications. Products must be available in the marketplace by May 15, 2026, and possess expiration dates of at least one year from manufacture with a minimum six-month shelf life at award.